RecruitingPhase 3NCT06570291

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells (AlloJoin®) Therapy for Knee Osteoarthritis.


Sponsor

Wuxi Cellular Biopharmaceutical Group Ltd.

Enrollment

520 participants

Start Date

Feb 28, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mesenchymal Stem Cells and a drug called Sodium Hyaluronate Injection for people with knee osteoarthritis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 40 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMesenchymal Stem Cells

Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use

DRUGSodium Hyaluronate Injection

Sodium Hyaluronate administrated for intra-articular use


Locations(2)

RenJi Hospital

Shanghai, China, China

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06570291


Related Trials